3rd Oct 2005 13:54
Oxford Biomedica PLC03 October 2005 FOR IMMEDIATE RELEASE 3 OCTOBER 2005 OXFORD BIOMEDICA ANNOUNCES APPOINTMENT OF EVOLUTION SECURITIES AS SOLE BROKER Oxford, UK: 3 October 2005 - Oxford BioMedica (LSE: OXB.L), the leading genetherapy company, today announces that it has appointed Evolution SecuritiesLimited as its sole broker. - Ends - For further information, please contact: Oxford BioMedica plc: Tel: +44(0)1865 783 000 Professor Alan Kingsman, Chief ExecutiveCity/Financial Enquiries: Tel: +44 (0)20 7466 5000 Lisa Baderoon/ Mark Court/ Mary-Jane JohnsonBuchanan Communications Scientific/Trade Press Enquiries: Tel: +44 (0)20 7886 8150Sue Charles/ Katja Stout/ Ashley LillyNorthbank Communications Notes to editors Oxford BioMedicaOxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical trials in 2006, and four furtherpreclinical candidates. The Company is underpinned by over 80 patent families,which represent one of the broadest patent estates in the field. The Company has a staff of approximately 65 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Viragen,MolMed and Kiadis; and has licensed technology to a number of companiesincluding Merck & Co, Biogen Idec and Pfizer. Further information is available at http://www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica